Key facts
- It has raised $120K; the latest was Angel (individual) ($120K) in Jan 2025.
- Notable investors include University of Santiago de Compostela.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Albor Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Albor Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Albor Biotech
Operator of a preclinical contract research organization intended to provide research services to pharmaceutical, biotechnology, nutraceutical companies, and research institutions. The company offers efficacy evaluation, validation studies, biomarker analysis, and related research services, enabling clients to support the assessment and optimization of drug candidates during early development stages.
- Sector
- Healthcare
- HQ
- Santiago de Compostela, Spain
- Employees
- 6
- Website
- alborbiotech.com/
- Ownership
- Privately Held (backing)
Albor Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Albor Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Albor Biotech in its N-PORT filings yet. We sweep new filings monthly.